Abstract: The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit of Escherichia coli heat-labile toxin.
Type:
Grant
Filed:
November 25, 2014
Date of Patent:
May 29, 2018
Assignees:
IDEMITSU KOSAN CO., LTD., NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
Abstract: The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.
Type:
Grant
Filed:
July 12, 2010
Date of Patent:
October 24, 2017
Assignees:
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, GLYCOBIOMARKER LEADING INNOVATION CO., LTD.
Abstract: The present invention provides an agent for controlling colibacillosis including a fusion protein comprising a subunit of Shiga toxin and a subunit of Escherichia coli heat-labile toxin.
Type:
Application
Filed:
November 25, 2014
Publication date:
February 2, 2017
Applicants:
IDEMITSU KOSAN CO., LTD., NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE
Abstract: Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
November 15, 2016
Assignees:
ID Pharma Co., Ltd., National Center for Global Health and Medicine
Abstract: Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.
Type:
Application
Filed:
April 26, 2012
Publication date:
May 22, 2014
Applicant:
National Center for Global Health and Medicine
Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease.
Type:
Application
Filed:
October 11, 2013
Publication date:
February 27, 2014
Applicants:
Sysmex Corporation, National Center for Global Health and Medicine, Nagoya City University, National Institute of Advanced Industrial Science and Technology
Abstract: An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Disclosed is a method for measuring at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject, comprising: measuring AGP binding to a first lectin selected from AOL and MAL, when the glycoprotein is AGP; and measuring M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII, when the glycoprotein is M2BP.
Type:
Grant
Filed:
January 13, 2012
Date of Patent:
January 7, 2014
Assignees:
Sysmex Corporation, National Institute of Advanced Industrial Science and Technology, Nagoya University, National Center for Global Health and Medicine
Abstract: The present invention provides a peptide comprising amino acid sequences R I, F I and R I G C and containing 25 or fewer amino acid residues, and capable of transporting a functional molecule into a cell, and also into a nucleus, more efficiently than a previous PTD.
Type:
Grant
Filed:
March 6, 2008
Date of Patent:
June 4, 2013
Assignee:
National Center for Global Health and Medicine
Abstract: The present invention relates to a method of testing for genetic susceptibility to type-2 diabetes in a subject that comprises detecting one or more polymorphisms present in the KCNQ1 gene and/or EIF2AK4 gene in a DNA-containing sample collected from the subject. The present invention permit a method of accurately, conveniently, and rapidly testing the genetic susceptibility of subjects to type-2 by targeting determinative genetic factors of genetic susceptibility to type-2 diabetes.
Type:
Application
Filed:
December 15, 2008
Publication date:
June 23, 2011
Applicants:
National Center for Global Health and Medicine, The University of Tokyo, National University Corporation Ehime University